Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung cancer
Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung cancer Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in The Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients. Using exploratory data analysis and process-mining techn...